Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy.
Paclitaxel is a new agent for advanced non-small cell lung cancer (NSCLC). Weekly doses may enhance antitumor activity while minimizing toxicity, but little is known about immune recovery. Paclitaxel (80 mg/m2) was administered to 10 patients with NSCLC, weekly during 3-week cycles. Natural killer (NK) activity, CD3-CD16+CD56+ NK cells, and differential counts were monitored. NK activity appeared in all patients after treatment with paclitaxel therapy NK activity showed a 27 +/- 9% decrease (mean +/- SE) on protocol day 8 and a 37 +/- 7% decrease on day 15 (p < 0.05) recovering to 89 +/- 5% of baseline on day 29. With weekly paclitaxel, a decrease in NK cell function persisted through the first cycle but then recovered. Weekly paclitaxel may be less immunosuppressive than agents such as cisplatin.
Sako
Takanori
T
Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Burioka
Naoto
N
Yasuda
Kazuhito
K
Tomita
Katsuyuki
K
Miyata
Masanori
M
Kurai
Jun
J
Chikumi
Hiroki
H
Watanabe
Masanari
M
Suyama
Hisashi
H
Fukuoka
Yasushi
Y
Ueda
Yasuto
Y
Shimizu
Eiji
E
D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000502:physiology; D007262:Infusions, Intravenous; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D011446:Prospective Studies; D018570:Risk Assessment; D012494:Sampling Studies; D016896:Treatment Outcome
D017239:Paclitaxel